2025年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 重要提示： ● 预计2025年度实现归属于上市公司股东的净利润105,500万元到121,500万元，同比增长64.20%到 89.11%。 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：000028、200028 证券简称：国药一致、一致B 公告编号：2026-01 国药集团一致药业股份有限公司 ● 预计2025年度实现归属于上市公司股东的扣除非经常性损益的净利润99,600万元到115,600万元，同比 增长71.38%到98.91%。 一、本期业绩预计情况 （一）业绩预告期间：2025年1月1日至2025年12月31日。 （二）业绩预告情况：预计净利润为正值且属于同向上升50%以上情形 ■ 二、与会计师事务所沟通情况 国药一致（简称"公司"）就业绩预告有关事项已与会计师事务所进行预沟通，公司与会计师事务所在业 绩预告方面不存在分歧。本次业绩预告相关的财务数据是公司财务部门初步估算得出，未经会计师事务 所审计。 三、业绩变动原因说明 2025年度，在行业政策复杂多变，市场竞 ...

Core Viewpoint - The company, China National Pharmaceutical Group Corporation (Sinopharm), expects significant growth in net profit for the fiscal year 2025, indicating strong financial performance and positive market outlook [1] Financial Projections - The company anticipates a net profit attributable to shareholders ranging from 1,055 million to 1,215 million yuan, representing a year-on-year growth of 64.20% to 89.11% [1] - The projected net profit, excluding non-recurring gains and losses, is expected to be between 996 million and 1,156 million yuan, with a year-on-year increase of 71.38% to 98.91% [1]

Core Viewpoint - China National Pharmaceutical Group Corporation (国药一致) forecasts a net profit attributable to shareholders of 1.055 billion to 1.215 billion yuan for 2025, representing a year-on-year growth of 64.2% to 89.11% [1] Group 1 - The company aims to continue its strategic transformation and refined management to further consolidate operational results [1] - The focus is on enhancing core competitiveness and achieving sustainable, high-quality development [1]

Core Viewpoint - The company, China National Pharmaceutical Group Corporation (国药一致), expects a significant increase in net profit for the fiscal year 2025, indicating strong resilience and operational vitality despite a challenging market environment [1] Financial Performance - The company anticipates a net profit attributable to shareholders ranging from 1,055 million to 1,215 million yuan for 2025, representing a year-on-year growth of 64.20% to 89.11% [1] - The expected net profit, excluding non-recurring gains and losses, is projected to be between 996 million and 1,156 million yuan, with a year-on-year increase of 71.38% to 98.91% [1] Operational Strategy - In a complex and competitive industry landscape, the company demonstrates strong development resilience through proactive structural adjustments and cost management, effectively curbing profit decline and achieving overall performance recovery [1] - The distribution business remains a cornerstone of the company's operations, continuing to show stable growth [1] - The company enhances operational quality by strengthening its procurement system, optimizing product structure, and strategically adjusting store layouts [1]

Core Viewpoint - The company, China National Pharmaceutical Group Corporation (国药一致), forecasts a significant increase in net profit for the year 2025, indicating strong resilience and operational vitality despite a challenging market environment [1] Financial Performance - The expected net profit attributable to shareholders for 2025 is projected to be between 105,500 million and 121,500 million yuan, representing a year-on-year increase of 64.20% to 89.11% [1] - The net profit after deducting non-recurring gains and losses is anticipated to be between 99,600 million and 115,600 million yuan, reflecting a year-on-year growth of 71.38% to 98.91% [1] Operational Strategy - The company has demonstrated strong operational resilience through proactive structural adjustments and cost control measures, effectively curbing the trend of profit decline and achieving overall performance recovery [1] - The distribution business remains a cornerstone of the company's operations, continuing to show stable growth [1] - The company has enhanced its operational quality by strengthening its procurement system, optimizing product structure, and strategically adjusting store layouts [1] Asset Management - Based on a cautious approach and preliminary assessments by a third-party professional evaluation agency, the company expects to recognize an impairment provision for goodwill and intangible assets between 24,000 million and 33,000 million yuan, which is a decrease of 63,992.83 million to 72,992.83 million yuan compared to the previous year [1] - Despite the impact of the aforementioned asset impairments, the company still anticipates a year-on-year increase in net profit attributable to shareholders of 64.20% to 89.11% [1]

Core Viewpoint - The company, China National Pharmaceutical Group Corporation (国药一致), forecasts a net profit attributable to shareholders of 1.055 billion to 1.215 billion yuan for 2025, representing a year-on-year growth of 64.20% to 89.11% [1] Group 1: Financial Performance - The expected net profit for 2025 is projected to be between 1.055 billion and 1.215 billion yuan [1] - This forecast indicates a significant increase in profitability, with a growth rate ranging from 64.20% to 89.11% compared to the previous year [1] Group 2: Business Operations - The distribution business remains a cornerstone of the company's operations, continuing to show stable growth [1] - The company has enhanced its procurement system, optimized product structure, and strategically adjusted store layouts to effectively improve operational quality [1]

（文章来源：每日经济新闻） 每经AI快讯，1月25日，国药一致公告，预计2025年度实现归属于上市公司股东的净利润10.55亿元到 12.15亿元，同比增长64.20%到89.11%。预计2025年度实现归属于上市公司股东的扣除非经常性损益的 净利润9.96亿元到11.56亿元，同比增长71.38%到98.91%。 ...

国药一致公告，预计2025年度实现归属于上市公司股东的净利润10.55亿元到12.15亿元，同比增长 64.20%到89.11%。预计2025年度实现归属于上市公司股东的扣除非经常性损益的净利润9.96亿元到 11.56亿元，同比增长71.38%到98.91%。 ...

Group 1 - The core point of the news is that Chongqing Pharmaceutical Holdings (重药控股) disclosed that seven of its subsidiaries have paid a total of 32.21 million yuan in back taxes and late fees [1] - The seven subsidiaries involved are Qinghai Pharmaceutical Co., Ltd., Inner Mongolia Zhelimeng Pharmaceutical Co., Ltd., Guizhou Pharmaceutical Group Co., Ltd., Guizhou Pharmaceutical Group He Ping Pharmaceutical Co., Ltd., Shaanxi Huashi Pharmaceutical Co., Ltd., Shaanxi Pharmaceutical Co., Ltd., and Chongqing Pharmaceutical Group (Gansu) Co., Ltd. [1] - The company stated that the back taxes and late fees were due to the self-examination of the subsidiaries regarding the income tax benefits enjoyed under the Western Development policy, with 7.46 million yuan due for 2025 and 24.75 million yuan for 2026 [1] Group 2 - For the first three quarters of 2025, Chongqing Pharmaceutical Holdings reported an operating income of 62.2 billion yuan, representing a year-on-year increase of 4.22% [2] - The net profit attributable to shareholders of the listed company was 384 million yuan, showing a year-on-year growth of 31.41% [2]

Investment Rating - The industry investment rating is "outperforming the market," indicating an expected relative increase of over 10% in the industry index compared to the broader market within the next six months [8]. Core Insights - The joint opinion from nine departments emphasizes support for prescription outflow, collaboration between retail and commercial insurance, equal treatment for outpatient services, and encourages mergers and acquisitions among pharmacies. This creates a favorable environment for leading pharmacy chains, opening a window for industry consolidation [4]. - The pharmacy industry has experienced a long-term supply-side clearing, leading to increased customer flow towards leading companies and a continuous rise in market concentration. With efforts to reduce costs and improve efficiency, performance is expected to continue improving, especially with the recent policy shift [4]. - The report suggests focusing on comprehensive pharmacy chains that have potential for mergers, clear business transformation progress, and strong capabilities for nationwide expansion or deep-rooted local market barriers. Future attention should be on policy implementation, store expansion, and performance improvement expectations [4]. Policy Highlights - The policy aims to optimize the service of designated retail pharmacies, allowing insured individuals to purchase drugs from these pharmacies with costs covered by insurance funds according to regulations. It also supports the use of personal accounts for medical expenses incurred at designated retail pharmacies [2]. - The policy encourages retail pharmacies to participate in centralized drug procurement and aims to build a commercial insurance payment guarantee system, promoting the development of commercial health insurance products that fit retail pharmacy scenarios [2][3]. - There is a push for retail pharmacies to engage in mergers and acquisitions, promoting integrated development between wholesale and retail sectors, and encouraging the sale of innovative drugs and reference preparations through retail channels [3].